TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

OLYSIO

SIMEPREVIR SODIUM
Approved 2013-11-22
5
Indications
--
Phase 3 Trials
2
Priority Reviews
12
Years on Market

Details

Status
Discontinued
First Approved
2013-11-22
Routes
ORAL
Dosage Forms
CAPSULE

Companies

Active Ingredient: SIMEPREVIR SODIUM

OLYSIO Approval History

Loading approval history...

What OLYSIO Treats

5 FDA approvals

Originally approved for its first indication in 2013 . Covers 5 distinct patient populations.

  • Other (5)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

OLYSIO FDA Label Details

Pro

OLYSIO Patents & Exclusivity

Latest Patent: Sep 2029

Patents (8 active)

US8148399 Expires Sep 5, 2029
US8349869 Expires Jul 28, 2026
US8754106 Expires Jul 28, 2026
US8741926 Expires Jul 28, 2026
US9040562 Expires Jul 28, 2026
US9856265 Expires Jul 28, 2026
US9353103 Expires Jul 28, 2026
US9623022 Expires Jul 28, 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.